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INTRODUCTION
Recipients of bone marrow transplants (BMTs) have an
immunodeficiency of varying duration and severity [1–4].
BMT recipients have an increased incidence of viral and bac-
terial infections indicating defects in both cellular and
humoral immunity. Recurrent infections with encapsulated
respiratory bacteria are a particular problem in the recipients
of unrelated BMT and the recipients of histocompatible trans-
plants with chronic graft-vs.-host disease (cGVHD) [3,4].
BMT recipients may have deficiencies in antibody production
following immunization with viral vaccines (measles, mumps,
rubella) or bacterial protein antigens (tetanus toxoid, f X174)
early after transplantation, whereas patients with cGVHD
have long-term defects in antibody responses to vaccination
with pneumococcal carbohydrate antigens [2]. The responses
of BMT recipients to endogenous wild-type bacterial carbo-
hydrate antigens have not been systematically studied. Anti-
body to polyribose phosphate (PRP), the capsular polysaccha-
ride of Haemophilus influenzae type b (Hib), can be induced by
stimulation with Hib organisms or by cross-reactivity with the
capsular polysaccharides of the K100 strains of Escherichia coli
that are normally found in the gastrointestinal tract [5,6].
We report here the long-term evaluation of the anticar-
bohydrate antibody responses of BMT recipients to natural-
ly occurring PRP and demonstrate that, while the anticar-
bohydrate antibody responses of the recipients of
autologous transplants undergo a recapitulation of the nor-
mal ontogeny of anticarbohydrate antibody responses,
significant and protracted defects in the antibody response
to wild-type bacterial PRP exist in all recipients of unrelated
BMT and a significant proportion of histocompatible recipi-
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ABSTRACT
The long-term recipients of allogeneic bone marrow transplantation (BMT) are at an increased risk of death due to
bacterial infections. We evaluated the anticarbohydrate antibody responses of BMT recipients to a naturally occur-
ring bacterial carbohydrate, polyribose phosphate (PRP). The recipients of autologous BMT achieved protective
anti-PRP levels (.100 ng/mL) by 3 years after transplantation, with a pattern consistent with a recapitulation of the
ontogeny of anticarbohydrate antibody responses. None of the six recipients of unrelated BMT who were off
immunosuppressive therapy had protective anti-PRP levels, though their response to a protein antigen (tetanus tox-
oid) was normal. Of 48 recipients of histocompatible BMT, 22 (46%) had protective anti-PRP antibody levels,
whereas 13 (27%) recipients who were .3 years post-BMT did not have protective levels. Therefore, all unrelated
recipients and a significant proportion of histocompatible recipients without clinical graft-vs.-host disease had per-
sistent and prolonged defects in their capacity to produce antibodies to naturally occurring bacterial carbohydrate
antigens. These results suggest that allogeneic BMT recipients should be longitudinally evaluated for their anticar-
bohydrate antibody responses and that patients with defective antibody responses should receive prophylactic
antibiotics or replacement immunoglobulin therapy or both to reduce their risk of late bacterial infections.
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ents who do not have detectable cGVHD. The sustained
persistence of defects in the anticarbohydrate antibody
responses of BMT recipients suggest that the long-term
administration of intravenous immunoglobulin or prophy-
lactic administration of antibiotics or both may be required
to protect BMT recipients with defective anticarbohydrate
antibody responses from significant bacterial infections. The
absence of clinical cGVHD does not guarantee that BMT
recipients are capable of normal antibody responses to wild-
type bacterial carbohydrate antigens.
PATIENTS AND METHODS
Study population and treatment
Patients between the ages of 4 months and 21 years with
both malignant leukemia and lymphoma, and non-malig-
nant aplastic anemia, severe combined immune deficiency,
and a variety of genetic diseases, and who had received
transplants at Children’s Hospital–Los Angeles between
December 1, 1983 and November 30, 1996 were included in
the study. The median patient age was 7.5 years and the
median donor age was 6 years. Patients received autologous,
histocompatible, or unrelated bone marrow (BM). The
majority of the patients with both malignant and nonmalig-
nant diseases were prepared for transplantation with busul-
fan (1 mg/kg q. 6 hours 3 16 doses) and cyclophosphamide
(16 mg/kg q.d. 3 4 days), except for patients with severe
aplastic anemia who did not receive busulfan. Recipients of
unrelated BM also received antithymocyte globulin (20 mg ·
kg–1 · day–1 3 4 days) before transplantation. BM for autolo-
gous transplants for acute leukemia was purged in vitro with
4-hydroperoxycyclophosphamide (4-HC) [7].
GVHD prophylaxis consisted of methotrexate alone for
histocompatible recipients ,10 years old and cyclosporine
plus methotrexate or steroids for histocompatible recipients
$10 years old and for all unrelated recipients. Immuno-
suppression was tapered by the attending physicians as 
tolerated by the patients. None of the patients were immu-
nized with either conjugated or unconjugated Hib vaccine.
Antibody assays
Antibodies to both PRP and tetanus toxoid were meas-
ured by an enzyme-linked immunosorbent assay (ELISA) as
previously described [8]. Briefly, PRP-human serum albu-
min conjugate (Richard Insel, University of Rochester
School of Medicine, NY) or tetanus toxoid (Wyeth Labora-
tories, Marettia, PA) were used to coat microtiter plates.
The immunoglobulin (Ig)G antibody content of patient
samples was determined with a goat antihuman antibody
conjugated to horseradish peroxidase. Plates were cultured
with o-phenylenediamine and the antibody content calculat-
ed from the optical density of triplicate samples compared
with a standard pool of normal human Ig. The minimum
antibody levels that can be routinely detected are 10 ng/mL
for PRP and 0.01 IU/mL for tetanus toxoid.
RESULTS
Autologous BMT
Seven of 14 evaluated recipients of 4-HC–purged autol-
ogous BMT had protective levels (.100 ng/mL) of anti-PRP
antibody. All patients who had non-protective levels of anti-
body were ,36 months posttransplantation when last evalu-
ated (Fig. 1A). Patient age had no impact on the likelihood of
patients having protective levels of anti-PRP antibody.
Unrelated BMT
Recipients of unrelated BM routinely received monthly
Ig replacement therapy while receiving immunosuppressive
therapy, thus their ability to produce antibodies could not be
assessed. None of the six recipients of unrelated marrow fol-




Figure 1. Relationship between anti-PRP antibody levels and time
from BMT
(A) Recipients of autologous BMT; (B) recipients of unrelated BMT; (C)
recipients of histocompatible BMT.
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PRP antibodies despite not having cGVHD and no longer
receiving Ig replacement or immunosuppressive therapies
(Fig. 1B). These patients were between 3 and 12 years old at
the time of their most recent assessment.
Histocompatible BMT
Anti-PRP antibody levels from 48 histocompatible BMT
recipients more than 1 year after transplantation are present-
ed in Figure 1C. Twenty-two (46%) patients had protective
levels of anti-PRP antibody, whereas 26 patients had nonpro-
tective levels, 13 (27%) of whom were .3 years post-BMT.
The impact of donor and recipient age on the produc-
tion of anti-PRP antibodies was analyzed. A positive corre-
lation existed between donor age and the levels of recipient
anti-PRP antibodies (r 5 0.28, p 5 0.04; Fig. 2A) while no
correlation was found between recipient age and anti-PRP
antibody levels (r 5 0.10, p 5 0.21; Fig. 2B).
Anti-PRP and antitetanus toxoid antibody levels
To determine if the inability of unrelated BMT recipi-
ents to produce protective levels of anticarbohydrate anti-
bodies was a generalized problem in antibody production or
was limited to carbohydrate antigens, their antibody respons-
es to a protein antigen (tetanus toxoid) were determined. In
all cases recipients were able to produce protective levels
(.0.1 IU/mL) of antibody to tetanus toxoid (Table 1).
DISCUSSION
Antibody-mediated protection against infection with
encapsulated respiratory bacteria (e.g., Haemophilus influenzae,
Staphylococci, Streptococci pneumococci) is mediated by antibodies
directed against carbohydrate antigens present in the bacteri-
al cell wall or capsule. Ontological delays in the capacity of
humans to produce anticarbohydrate antibodies result in an
increased incidence of invasive bacterial infections once the
protection of transplacentally-derived maternal IgG is lost
[6]. Following BMT, a similar ontogeny in the antibody
response to bacterial carbohydrate antigens occurs.
In the present study, the recipients of autologous 
4-HC–treated BMT recovered protective levels of anti-
carbohydrate antibodies in a time course similar to that seen
in normal human ontogeny (i.e., protective antibody levels
were present in all recipients by 2–3 years following BMT,
though many recipients did not have protective levels before
2–3 years). Previous studies evaluating the transfer of
mature antibody-producing B cells has demonstrated a lack
of transfer of antigen-specific B lymphocytes unless the
donor is reimmunized before transplantation and the recipi-
ent is immunized following transplantation [9–11]. Thus,
the development of antibody responses to both protein and
carbohydrate antigens after transplantation is due to either
the clonal expansion of the limited number of antigen-
specific B lymphocytes transferred at the time of transplan-
tation or the generation of new antigen-specific B lympho-
cytes following hematopoietic stem cell engraftment.
Although delays in the production of anticarbohydrate anti-
bodies may be present during the first 3 years after autolo-
gous BMT, all patients did develop antibody responses to a
protein antigen (tetanus toxoid) by 1 year after immuniza-
tion (data not presented). Thus, delays in the development
of anticarbohydrate antibodies are not part of a generalized
defect in antibody production.
When recipients of histocompatible BMT were evaluat-
ed, approximately one-half of the patients had protective
levels of anticarbohydrate antibodies. The patients who did
not have protective levels of antibodies could be divided into
two groups. Recipients who were ,3 years post-BMT
might be expected to have an ontological inability to pro-
duce anticarbohydrate antibodies, whereas those recipients
who were more than 36 months post-BMT would be
expected to have protective levels of anti-PRP antibody.
Thirteen patients who were .36 months post-BMT and
not on immunosuppressive therapy had a lack of protective
levels of anticarbohydrate antibodies for as long as 6 years
after BMT, although they were capable of normal anti-
tetanus toxoid antibody responses (data not shown). Five of
the patients had no detectable anticarbohydrate antibodies
Figure 2. Regression analysis of relationship between age and anti-PRP antibody levels
(A) Relationship between histocompatible donor age and anti-PRP antibody levels and (B) histocompatible patient age and anti-PRP antibody levels.
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(,10 ng/mL) for up to 78 months posttransplant. Thus, a
subset of histocompatible BMT recipients without clinical
evidence of cGVHD had persistent defects in the produc-
tion of anticarbohydrate antibodies despite normal antibody
responses to protein antigens.
Our results confirm those of other studies that demon-
strated that BMT recipients could respond to immunization
with protein antigens by 1 year, whereas the majority of the
patients (84%) were unable to respond to immunization
with purified pneumococcal polysaccharide antigens for up
to 2 years [11–14]. As in human infants, BMT recipients are
capable of responding to immunization with conjugated
PRP vaccines [11,14–17]. The ability to respond to a conju-
gated carbohydrate vaccine, however, does not predict the
capacity of a BMT recipient to respond to wild-type PRP, as
demonstrated in the present study.
Many recipients of unrelated BMT remain on immuno-
suppressive therapy because of cGVHD, making the evalua-
tion of their ability to make anticarbohydrate antibodies dif-
ficult. However, six patients who were no longer receiving
immunosuppressive therapy had nonprotective levels of
anticarbohydrate antibodies for as long as 6 years following
BMT and 3–4 years following the cessation of their
immunosuppressive therapy. Thus, sustained and potentially
permanent defects in the ability of BMT recipients to pro-
duce protective levels of anticarbohydrate antibodies may
exist in both recipients of unrelated BMT as well as some
histocompatible recipients. Unrelated BMT recipients have
an increased incidence of late-infection mortality unrelated
to their GVHD status [4]. The basis for the protracted
inability of some BMT recipients to produce antibodies to
wild-type carbohydrate antigens is unknown.
Because of the inability of some BMT recipients to pro-
duce protective levels of anticarbohydrate antibodies, our
standard practice is to maintain such patients on daily
antibiotic prophylaxis (trimethoprim-sulfamethoxazole)
against bacterial infections until they can produce protective
levels of anticarbohydrate antibodies. Many transplant pro-
grams routinely administer prophylactic antibiotics for only
1 year after BMT and do not assess the ability of their
patients to produce anticarbohydrate antibodies. The lack of
protective levels of anticarbohydrate antibodies in conjunc-
tion with the absence of Ig therapy or antibiotic prophylaxis
may contribute to the increased incidence of invasive bacte-
rial infections seen in long-term survivors of BMT.
Studies should be undertaken to determine if long-term
recipients, especially of unrelated BM, can respond to
immunization with conjugated polysaccharide vaccines. The
development of protective antibody levels after immuniza-
tion with conjugated vaccines (Hib, pneumococci), however,
will not indicate that such recipients can develop protective
immunity to wild-type encapsulated bacteria (e.g., Staphylo-
cocci, Streptococci, and Meningococci).
We have previously reported that the capacity of BMT
recipients to produce new CD41 T lymphocytes (CD41,
CD45RA1 cells) is predictive of their capacity to develop T-
lymphocyte proliferative responses to tetanus toxoid following
transplantation [18]. We anticipated, therefore, that an inverse
correlation might exist between patient age and anti-PRP
antibody levels since in humans, as opposed to mice, anticar-
bohydrate antibody responses are T lymphocyte–dependent.
Thus, defects in the capacity of the thymus to produce new T
lymphocytes might be manifested by a decreased capacity to
produce anticarbohydrate antibodies. No correlation between
patient age and anti-PRP levels was found. However, the max-
imum age of the patients in the present study was only 20
years, whereas in our previous study, patients as old as 45 years
were evaluated. Thus, the negative impact of decreased thymic
function on anticarbohydrate antibody production may only
be observed in older patients.
The molecular basis for the normal ontological delay in
production of antibodies to carbohydrates compared with
protein antigens is unknown. Immunization with carbohy-
drate antigens conjugated to immunogenic proteins (conju-
gated vaccines) results in protective immunization, suggest-
ing that defects in the processing or presentation of
unconjugated carbohydrate antigens to T lymphocytes may
exist. When normal infants or BMT recipients are immu-
nized with conjugated PRP antigen, protective antibody
responses are obtained demonstrating that the T and B
lymphocyte interactions necessary for the production of
anticarbohydrate antibodies exist following transplantation
if the carbohydrate antigen is presented in an immunogenic
manner [11–17].
In a previous study, a correlation between both donor
and recipient age and the ability of BMT recipients to
respond to conjugated PRP immunization was seen [11]. In
the study, we noted a correlation between donor and recipi-
ent age, therefore, the relative contribution of the donor
and recipient could not be evaluated. In the present study,
no correlation between donor and recipient age existed (r 5
–0.04); however, a correlation between donor age, but not
recipient age, and the development of protective anti-PRP
antibody levels was found. The fact that older donors pro-
duced higher levels of posttransplant anticarbohydrate anti-
bodies suggests that either there is the transfer of more
primed donor B lymphocytes at the time of transplantation
or that B lymphocytes derived from older hematopoietic
stem cells have a greater capacity to respond to carbohy-
drate antigens.
This study demonstrates that significant and protracted
defects in the production of protective levels of anticarbohy-
drate antibodies to naturally occurring bacteria exist in the
recipients of allogeneic BMT despite their documented abil-
ity to produce antibodies to protein antigens and conjugated
polysaccharide vaccines. The defects in the production of
Table 1. Comparison of anti-PRP (PRP) and tetanus toxoid (TT) antibody
levels in recipients of unrelated BMT
Time post-BMT PRPa TTb
Patient (months) (ng/mL) (IU/mL)
1 74 572 3.0
2 57 510 8.0
3 54 ,10 3.0
4 43 ,10 2.1
5 31 517 4.4
6 26 ,10 3.0
aProtective level, .100 ng/mL.
bProtective level, .0.1 IU/mL.
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anticarbohydrate antibodies may, therefore, contribute to
the increased incidence of severe and potentially fatal inva-
sive bacterial infections seen in long-term survivors of unre-
lated BMT and histocompatible recipients with cGVHD.
These results suggest that the routine assessment of the
capacity of BMT recipients to produce anticarbohydrate
antibodies to wild-type bacteria is indicated. Patients who
have defects in anticarbohydrate antibody production might
be treated in a fashion analogous to patients with congenital
or acquired agammaglobulinemia, i.e., the administration of
prophylactic antibodies or the routine administration of
replacement immunoglobulin therapy or both.
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